A Phase 3, Multicenter, Randomized, Controlled Trial to Evaluate Immune Equivalence and Safety of Multidose and Single-dose Formulations of Vi-DT Typhoid Conjugate Vaccine in Healthy Filipino Individuals 6 Months to 45 Years of Age.

MLA

Carlos, Josefina Cadorna, et al. “A Phase 3, Multicenter, Randomized, Controlled Trial to Evaluate Immune Equivalence and Safety of Multidose and Single-Dose Formulations of Vi-DT Typhoid Conjugate Vaccine in Healthy Filipino Individuals 6 Months to 45 Years of Age.” The Lancet Regional Health. Western Pacific, vol. 24, May 2022, p. 100484. EBSCOhost, https://doi.org/10.1016/j.lanwpc.2022.100484.

APA

Carlos, J. C., Tadesse, B. T., Borja-Tabora, C., Alberto, E., Ylade, M. C., Sil, A., Kim, D. R., Ahn, H. S., Yang, J. S., Lee, J. Y., Kim, M. S., Park, J., Kwon, S.-Y., Kim, H., Yang, S.-Y., Ryu, J.-H., Park, H., Shin, J.-H., Lee, Y., … Sahastrabuddhe, S. (2022). A Phase 3, Multicenter, Randomized, Controlled Trial to Evaluate Immune Equivalence and Safety of Multidose and Single-dose Formulations of Vi-DT Typhoid Conjugate Vaccine in Healthy Filipino Individuals 6 Months to 45 Years of Age. The Lancet Regional Health. Western Pacific, 24, 100484. https://doi.org/10.1016/j.lanwpc.2022.100484

Chicago

Carlos, Josefina Cadorna, Birkneh Tilahun Tadesse, Charissa Borja-Tabora, Edison Alberto, Michelle C Ylade, Arijit Sil, Deok Ryun Kim, et al. 2022. “A Phase 3, Multicenter, Randomized, Controlled Trial to Evaluate Immune Equivalence and Safety of Multidose and Single-Dose Formulations of Vi-DT Typhoid Conjugate Vaccine in Healthy Filipino Individuals 6 Months to 45 Years of Age.” The Lancet Regional Health. Western Pacific 24 (May): 100484. doi:10.1016/j.lanwpc.2022.100484.